Perioperative Etomidate and Early Risk After Hip Fracture Surgery
Perioperative etomidate exposure was associated with worse short-term outcomes after hip fracture surgery in a large matched cohort drawn from the TriNetX Research Network. The signal was strongest for 30-day mortality, where the anesthetic induction agent was linked to a clear increase in death risk during the first postoperative month. A lower rate of acute kidney injury emerged in the same analysis, creating a mixed safety profile that deserves careful interpretation at the bedside.
Etomidate occupies a familiar place in anesthesia because it preserves hemodynamic stability during induction, a feature that often makes it attractive for frail older adults with limited cardiovascular reserve. The concern is equally familiar: even brief exposure can suppress adrenal steroid synthesis, and that transient endocrine effect may matter when patients are already under the physiologic strain of trauma, surgery, blood loss, pain, and immobilization. Hip fracture care sits squarely in that vulnerable zone, where even modest physiologic perturbations can translate into pneumonia, cardiovascular events, or death.
Matched Cohort Design and Postoperative Endpoints
Investigators used a 1:1 matched cohort design to compare adults undergoing hip fracture surgery who received perioperative etomidate with matched controls who did not. After matching, the analysis included 6,246 patients in each group, and baseline characteristics were balanced between arms. The primary endpoint was 30-day mortality. Secondary outcomes included pneumonia, sepsis, venous thromboembolism, major adverse cardiovascular events, and acute kidney injury.
The 30-day results were not subtle. Etomidate exposure was associated with higher odds of mortality, with an odds ratio of 1.35 and a 95% confidence interval of 1.15 to 1.60. The association reached strong statistical significance, with _P_ less than 0.001. Pneumonia also increased, with an odds ratio of 1.23, while major adverse cardiovascular events rose to an odds ratio of 1.20. Acute kidney injury moved in the opposite direction, with an odds ratio of 0.83.
Short-term postoperative physiology seemed to diverge almost immediately.
Why Adrenal Suppression May Matter in Fragile Older Adults
The most biologically plausible explanation for the mortality signal is etomidate’s transient suppression of adrenal steroidogenesis. Cortisol is not an abstract laboratory number in this setting; it helps maintain vascular tone, modulate inflammatory responses, and support metabolic adaptation after surgical stress. When adrenal reserve is blunted in a patient recovering from hip fracture repair, the downstream effects can include reduced capacity to mount an effective stress response, greater susceptibility to infection, and poorer cardiovascular tolerance.
Pneumonia fits that framework well. Elderly patients after hip fracture surgery often experience impaired mobility, postoperative pain, opioid exposure, delirium risk, and reduced inspiratory effort, all of which can predispose to pulmonary complications. If adrenal suppression contributes to immune dysregulation or prolonged physiologic vulnerability, the pneumonia signal becomes easier to understand. The rise in major adverse cardiovascular events also aligns with a stress-response model, since perioperative hemodynamic instability and myocardial demand-supply imbalance remain major threats in this population.
The lower acute kidney injury rate is harder to reconcile mechanistically. It may reflect residual confounding, differences in hemodynamic management, or selection patterns that persisted even after matching. Retrospective database studies can balance measured variables, but they cannot fully eliminate treatment-selection bias, anesthetic nuance, or intraoperative clinical judgment. A finding in one renal endpoint does not erase the broader signal across mortality, pulmonary events, and cardiovascular complications.
Extended Follow-up Diluted the Signal
By 30 to 180 days, the associations attenuated and no longer remained statistically significant. That pattern suggests the excess risk concentrated in the early postoperative window, when anesthetic choice, operative stress, and immediate recovery likely carry the greatest weight. It also suggests that any effect of etomidate may be transient rather than sustained, which is consistent with its short pharmacologic action and brief adrenal suppression. Even so, a transient exposure can still shape outcomes if it occurs during a period of maximal physiologic fragility.
The absence of a significant association with sepsis or venous thromboembolism narrows the signal without neutralizing it. The postoperative course after hip fracture surgery is influenced by many moving parts, and not every complication pathway is likely to be affected by the same anesthetic exposure. Mortality, pneumonia, and major adverse cardiovascular events may be more sensitive to the stress-response disruption than infection or thrombosis, especially in a cohort where early respiratory and cardiovascular decompensation can dominate the clinical trajectory.
What This Means for Anesthetic Choice at the Bedside
For anesthesiologists and perioperative teams, these findings push etomidate into a more cautious category for hip fracture surgery. Its hemodynamic advantages remain real, especially in unstable patients, but the tradeoff may be less forgiving than many clinicians assume when the procedure involves older adults with limited physiologic reserve. A drug selected to protect blood pressure during induction may still influence the postoperative course through endocrine suppression and downstream vulnerability to respiratory or cardiovascular complications.
The study does not establish causation, and it does not provide a rule that etomidate should never be used. It does, however, argue against casual use when other induction strategies are feasible and when the patient’s perioperative risk profile already looks precarious. Clinical judgment still has to weigh immediate hemodynamic needs against possible short-term harm after surgery, especially in geriatric fracture care where the margin for error is small.
Prospective confirmation remains necessary. Randomized data would be needed to separate drug effect from treatment selection, to examine dose and timing more precisely, and to determine whether any subgroups derive net benefit or net harm. Until then, the available evidence supports heightened caution when etomidate is considered for hip fracture surgery, particularly in patients whose postoperative recovery may already be threatened by pulmonary or cardiovascular vulnerability.